Yungjin Pharm. Co., Ltd. (KRX:003520)
South Korea
· Delayed Price · Currency is KRW 2,080.00
0.00 (0.00%)
Last updated: Aug 14, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY undefined | FY undefined | FY undefined | FY undefined | FY undefined | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
| Antibiotics | 51.95B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics Growth | 12.52% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Intravenous and Enteral Nutrition | 44.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Intravenous and Enteral Nutrition Growth | 5.31% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Circulatory System | 29.61B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Circulatory System Growth | 4.52% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Finished Products and Raw Materials | 27.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Finished Products and Raw Materials Growth | 14.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuropsychiatric System | 23.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Neuropsychiatric System Growth | 11.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antipyretic, Analgesic and Anti-inflammatory | 16.46B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Antipyretic, Analgesic and Anti-inflammatory Growth | -13.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory System | 13.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory System Growth | 8.26% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Digestive System | 12.58B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Digestive System Growth | 14.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Processed Goods | 4.53B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Processed Goods Growth | 18.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 27.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 4.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 27.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 4.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY undefined | FY undefined | FY undefined | FY undefined | FY undefined | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
| Other | 2.34B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 126.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea | 224.46B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | 6.49% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan | 23.95B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth | 23.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Taiwan | 1.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Taiwan Growth | -64.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 2.34B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | 126.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Sweden | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|